D. Boral Capital Reiterates “Buy” Rating for Can-Fite BioPharma (NYSE:CANF)

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock. D. Boral Capital’s price target would indicate a potential upside of 476.37% from the company’s current price.

Separately, StockNews.com initiated coverage on Can-Fite BioPharma in a research note on Saturday. They set a “sell” rating on the stock.

Can-Fite BioPharma Stock Up 5.2 %

NYSE:CANF traded up $0.09 during trading hours on Tuesday, hitting $1.74. 1,537,110 shares of the company traded hands, compared to its average volume of 181,582. The firm’s 50-day simple moving average is $1.58 and its 200-day simple moving average is $1.88. Can-Fite BioPharma has a one year low of $1.29 and a one year high of $4.69. The company has a market cap of $6.14 million, a PE ratio of -0.97 and a beta of 1.12.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned approximately 0.71% of Can-Fite BioPharma at the end of the most recent quarter. 21.00% of the stock is owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.